866-997-4948(US-Canada Toll Free)

Multiple Myeloma (Kahler\'s Disease) Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Metabolic Disorders

No. of Pages : 622 Pages


Global Markets Directs, \'Multiple Myeloma (Kahler\'s Disease) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma (Kahler\'s Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler\'s Disease). 

Multiple Myeloma (Kahler\'s Disease) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Multiple Myeloma (Kahler\'s Disease).
  • A review of the Multiple Myeloma (Kahler\'s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Multiple Myeloma (Kahler\'s Disease) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler\'s Disease).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler\'s Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 6
Multiple Myeloma (Kahler\'s Disease) Overview 7
Therapeutics Development 8
Multiple Myeloma (Kahler\'s Disease) Therapeutics under Development by Companies 10
Multiple Myeloma (Kahler\'s Disease) Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 23
Mid Clinical Stage Products 24
Early Clinical Stage Products 25
Discovery and Pre-Clinical Stage Products 26
Multiple Myeloma (Kahler\'s Disease) Therapeutics Products under Development by Companies 27
Multiple Myeloma (Kahler\'s Disease) Therapeutics Products under Investigation by Universities/Institutes 39
Companies Involved in Multiple Myeloma (Kahler\'s Disease) Therapeutics Development 42
Multiple Myeloma (Kahler\'s Disease) Therapeutics Assessment 127
Drug Profiles 134
Multiple Myeloma (Kahler\'s Disease) Therapeutics Drug Profile Updates 440
Multiple Myeloma (Kahler\'s Disease) Therapeutics Discontinued Products 579
Multiple Myeloma (Kahler\'s Disease) Therapeutics - Dormant Products 582
Multiple Myeloma (Kahler\'s Disease) Product Development Milestones 591

Appendix 602

List of Table


Number of Products Under Development for Multiple Myeloma (Kahler\'s Disease), H1 2013 27
Products under Development for Multiple Myeloma (Kahler\'s Disease) Comparative Analysis, H1 2013 28
Number of Products under Development by Companies, H1 2013 30
Number of Products under Development by Companies, H1 2013 (Contd..1) 31
Number of Products under Development by Companies, H1 2013 (Contd..2) 32
Number of Products under Development by Companies, H1 2013 (Contd..3) 33
Number of Products under Development by Companies, H1 2013 (Contd..4) 34
Number of Products under Development by Companies, H1 2013 (Contd..5) 35
Number of Products under Development by Companies, H1 2013 (Contd..6) 36
Number of Products under Development by Companies, H1 2013 (Contd..7) 37
Number of Products under Investigation by Universities/Institutes, H1 2013 39
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 40
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 41
Comparative Analysis by Late Stage Development, H1 2013 42
Comparative Analysis by Mid Clinical Stage Development, H1 2013 43
Comparative Analysis by Early Clinical Stage Development, H1 2013 44
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 45
Products under Development by Companies, H1 2013 46
Products under Development by Companies, H1 2013 (Contd..1) 47
Products under Development by Companies, H1 2013 (Contd..2) 48
Products under Development by Companies, H1 2013 (Contd..3) 49
Products under Development by Companies, H1 2013 (Contd..4) 50
Products under Development by Companies, H1 2013 (Contd..5) 51
Products under Development by Companies, H1 2013 (Contd..6) 52
Products under Development by Companies, H1 2013 (Contd..7) 53
Products under Development by Companies, H1 2013 (Contd..8) 54
Products under Development by Companies, H1 2013 (Contd..9) 55
Products under Development by Companies, H1 2013 (Contd..10) 56
Products under Development by Companies, H1 2013 (Contd..11) 57
Products under Investigation by Universities/Institutes, H1 2013 58
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 59
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 60
Bristol-Myers Squibb Company, H1 2013 61
Johnson & Johnson, H1 2013 62
F. Hoffmann-La Roche Ltd., H1 2013 63
Kyowa Hakko Kirin Co., Ltd., H1 2013 64
Amgen Inc., H1 2013 65
Sanofi-Aventis, H1 2013 66
Eli Lilly and Company, H1 2013 67
Viralytics Ltd., H1 2013 68
GlaxoSmithKline plc, H1 2013 69
Seattle Genetics, Inc., H1 2013 70
Genentech, Inc., H1 2013 71
Gilead Sciences, Inc., H1 2013 72
Biotest AG, H1 2013 73
medac GmbH, H1 2013 74
Merck & Co., Inc., H1 2013 75
AbGenomics International, Inc., H1 2013 76
BioLineRx, Ltd., H1 2013 77
Amorfix Life Sciences Ltd., H1 2013 78
ZIOPHARM Oncology, Inc., H1 2013 79
Millennium Pharmaceuticals, Inc., H1 2013 80
Novartis AG, H1 2013 81
Astellas Pharma Inc., H1 2013 82
ImmunoGen, Inc., H1 2013 83
Nippon Kayaku Co., Ltd., H1 2013 84
Pfizer Inc., H1 2013 85
Sigma-Tau S.p.A., H1 2013 86
SuperGen, Inc., H1 2013 87
Teva Pharmaceutical Industries Limited, H1 2013 88
Santaris Pharma A/S, H1 2013 89
Exelixis, Inc., H1 2013 90
Aduro BioTech, H1 2013 91
Celgene Corporation, H1 2013 92
Onyx Pharmaceuticals, Inc., H1 2013 93
Incyte Corporation, H1 2013 94
Geron Corporation, H1 2013 95
XTL Biopharmaceuticals Ltd., H1 2013 96
MannKind Corporation, H1 2013 97
Merck KGaA, H1 2013 98
4SC AG, H1 2013 99
EntreMed, Inc., H1 2013 100
Celldex Therapeutics, Inc., H1 2013 101
AEterna Zentaris Inc., H1 2013 102
ImmunoCellular Therapeutics, Ltd., H1 2013 103
Ligand Pharmaceuticals Incorporated, H1 2013 104
Oncolytics Biotech Inc., H1 2013 105
Compugen Ltd., H1 2013 106
Patrys Limited, H1 2013 107
Curis, Inc., H1 2013 108
Telik, Inc., H1 2013 109
VioQuest Pharmaceuticals, Inc., H1 2013 110
Pharmacyclics, Inc., H1 2013 111
Array BioPharma Inc., H1 2013 112
XOMA Ltd., H1 2013 113
BioInvent International AB, H1 2013 114
Senesco Technologies, Inc., H1 2013 115
Threshold Pharmaceuticals, Inc., H1 2013 116
Synta Pharmaceuticals Corp., H1 2013 117
Innate Pharma SA, H1 2013 118
Transgene Biotek Ltd, H1 2013 119
Cellerant Therapeutics, Inc., H1 2013 120
Chroma Therapeutics Ltd., H1 2013 121
Avaris, H1 2013 122
Abiogen Pharma S.p.A., H1 2013 123
Acceleron Pharma, Inc., H1 2013 124
Coronado Biosciences, Inc., H1 2013 125
Arno Therapeutics, Inc., H1 2013 126
Vaccinex, Inc., H1 2013 127
CanBas Co., Ltd., H1 2013 128
Axelar AB, H1 2013 129
Immune System Therapeutics Ltd., H1 2013 130
NOXXON Pharma AG, H1 2013 131
Xencor, Inc., H1 2013 132
Tragara Pharmaceuticals, Inc., H1 2013 133
PharmaMar, S.A., H1 2013 134
AmpliMed Corporation, H1 2013 135
AB Science, H1 2013 136
Cylene Pharmaceuticals, Inc., H1 2013 137
Nereus Pharmaceuticals, Inc., H1 2013 138
TaiGen Biotechnology Co., Ltd., H1 2013 139
AVEO Pharmaceuticals, Inc., H1 2013 140
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., H1 2013 141
Elara Pharmaceuticals GmbH, H1 2013 142
Kyowa Hakko Kirin Pharma, Inc., H1 2013 143
Gliknik, Inc., H1 2013 144
Advancell, H1 2013 145
Assessment by Monotherapy Products, H1 2013 146
Assessment by Combination Products, H1 2013 147
Assessment by Stage and Route of Administration, H1 2013 149
Assessment by Stage and Molecule Type, H1 2013 152
Multiple Myeloma (Kahler\'s Disease) Therapeutics Drug Profile Updates 459
Multiple Myeloma (Kahler\'s Disease) Therapeutics Discontinued Products 598
Multiple Myeloma (Kahler\'s Disease) Therapeutics Discontinued Products (Contd..1) 599
Multiple Myeloma (Kahler\'s Disease) Therapeutics Discontinued Products (Contd..2) 600
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products 601
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..1) 602
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..2) 603
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..3) 604
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..4) 605
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..5) 606
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..6) 607
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..7) 608
Multiple Myeloma (Kahler\'s Disease) Therapeutics Dormant Products (Contd..8) 609

List of Chart


Number of Products under Development for Multiple Myeloma (Kahler\'s Disease), H1 2013 27
Products under Development for Multiple Myeloma (Kahler\'s Disease) Comparative Analysis, H1 2013 28
Products under Development by Companies, H1 2013 29
Products under Investigation by Universities/Institutes, H1 2013 38
Late Stage Products, H1 2013 42
Mid Clinical Stage Products, H1 2013 43
Early Clinical Stage Products, H1 2013 44
Discovery and Pre-Clinical Stage Products, H1 2013 45
Assessment by Monotherapy Products, H1 2013 146
Assessment by Combination Products, H1 2013 147
Assessment by Route of Administration, H1 2013 148
Assessment by Stage and Route of Administration, H1 2013 149
Assessment by Molecule Type, H1 2013 150
Assessment by Stage and Molecule Type, H1 2013 151

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *